Post Stroke Spastic Hemiplegia
Conditions
Keywords
Botulinum toxin, Spasticity, Stroke, Treatment Discontinuation
Brief summary
This study aims to evaluate patient adherence to botulinum toxin (BoNT-A) treatment and identify the factors contributing to its discontinuation. This retrospective cohort study analyzed the medical records of patients who received at least one botulinum toxin treatment for post-stroke spasticity (PSS) from 2012 to 2024. Eighty-one enrolled patients responded to structured questions about their reasons for not consistently continuing BoNT-A treatment.
Interventions
OTHERprovide information by phone
Previous studies did not question why patients thought they did not benefit from the injection. For example, the expectations of patients who said they did not benefit were excessive.
Sponsors
Suleyman Demirel University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* included chronic-phase ischemic or hemorrhagic stroke and spasticity in the upper and/or lower limbs.
Exclusion criteria
* Patients younger than 18 years, those who had passed away, and those who could not be reached by phone were excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome | 2012-2024 | Most PSS patients received only one BoNT-A injection over 12 years |
Countries
Turkey (Türkiye)
Outcome results
None listed